Abstract Number: 200 • 2017 ACR/ARHP Annual Meeting
Implementation and Evaluation of a Novel Nurse-Led Telemedicine Intervention for Dose Escalation of Urate-Lowering Therapy in Gout: A Clinical Practice Improvement Project
Background/Purpose: Urate-lowering therapy (ULT) is the mainstay of gout treatment. In our clinics, time to achieve target serum urate (SU) level during ULT titration was…Abstract Number: 341 • 2017 ACR/ARHP Annual Meeting
Understanding Perceptions and Experience of Gout through Linguistic Analysis of Online Search Activities
Background/Purpose: Online search engines are widely used to seek information about disease and management strategies. The aim of this study was to understand what terms…Abstract Number: 350 • 2017 ACR/ARHP Annual Meeting
Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State
Background/Purpose: Treatment targets for gout generally focus on serum urate, but patient-centred targets may be equally important. We seek to determine the relationship between gout…Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…Abstract Number: 981 • 2017 ACR/ARHP Annual Meeting
The Common Risk Factors for Hyperuricemia and Gout Do Not Predict Incident Gout Once Hyperuricemia Is Established
Background/Purpose: Metabolic syndrome, chronic kidney disease and hypertension are known to be associated with hyperuricemia and gout. Hypertension is associated with incident gout. The Normative…Abstract Number: 1021 • 2017 ACR/ARHP Annual Meeting
GWAS of Gout in Patients with Hyperuricemia Identified Many Possible New Candidate Risk Alleles
Background/Purpose: Virtually all gout patients have high levels of uric acid in the blood (hyperurincemia, HU), but approximately 80% of patients with HU will never…Abstract Number: 1090 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout
Background/Purpose: In patients with gout, hyperuricemia leads to inflammation induced by mono-sodium urate crystal deposition. This causes irreversible physical and radiographically evident destruction of the…Abstract Number: 1091 • 2017 ACR/ARHP Annual Meeting
The Utility of Electronic Consultation in the Management of Gout at the Veterans Affairs Medical Center
Background/Purpose: Gout is the most common inflammatory arthritis in adults worldwide. It can be managed by primary care physicians (PCPs), but complex cases often require…Abstract Number: 1104 • 2017 ACR/ARHP Annual Meeting
A Genome-Wide Association Study of Gout in People of European Ancestry
A genome-wide association study of gout in people of European ancestryBackground/Purpose: Genome wide association studies (GWAS) have provided considerable insight into the molecular control of…Abstract Number: 1107 • 2017 ACR/ARHP Annual Meeting
An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Background/Purpose: Gout is a chronic disease caused by deposition of monosodium urate crystals. Although diet is a risk factor, many other factors also contribute to…Abstract Number: 1109 • 2017 ACR/ARHP Annual Meeting
Sex Differences in Gout Patients: Epidemiology, Flares and Hospitalization Data in a Population Based Cohort
Background/Purpose: While gout is the most common form of inflammatory arthritis, there are relatively few studies on the influence of sex with regard to disease…Abstract Number: 1110 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack
Background/Purpose: To investigate the clinical features and risk of gout recurrence in patients with normouricemia during an acute attack Methods: This study was conducted in…Abstract Number: 1111 • 2017 ACR/ARHP Annual Meeting
Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease
Background/Purpose: There is increasing evidence that allopurinol may be protective of kidney function among hyperuricemic subjects, though clinicians are often cautious about using allopurinol in…Abstract Number: 1112 • 2017 ACR/ARHP Annual Meeting
Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout
Background/Purpose: Despite the use of corticosteroids in acute gout, there exist wide variations in treatment doses and duration. No studies have evaluated the ideal dose…Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »